It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
An expression quantitative trait locus (eQTL) single-nucleotide polymorphism (SNP) at rs9264942 was earlier associated with human leukocyte antigen (HLA)-C expression in Europeans. HLA-C has also been related to inflammatory bowel disease (IBD) risk in the Japanese. This study examined whether an eQTL SNP at rs9264942 could regulate HLA-C expression and whether four SNP haplotypes, including the eQTL SNP at rs9264942 and three SNPs at rs2270191, rs3132550, and rs6915986 of IBD risk carried in the HLA-C*12:02~B*52:01~DRB1*15:02 allele, were associated with IBD in the Japanese. HLA-C expression on CD3e+CD8a+ lymphocytes was significantly higher for the CC or CT genotype than for the TT genotype of rs9264942. The TACC haplotype of the four SNPs was associated with a strong susceptibility to ulcerative colitis (UC) but protection against Crohn’s disease (CD) as well as with disease clinical outcome. While UC protectivity was significant but CD susceptibility was not for the CGTT haplotype, the significance of UC protectivity disappeared but CD susceptibility reached significance for the CGCT haplotype. In conclusion, our findings support that the eQTL SNP at rs9264942 regulates HLA-C expression in the Japanese and suggest that the four SNPs, which are in strong linkage disequilibrium, may be surrogate marker candidates of a particular HLA haplotype, HLA-C*12:02~B*52:01~DRB1*15:02, related to IBD susceptibility and disease outcome.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Shinshu University School of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, Matsumoto, Japan (GRID:grid.263518.b) (ISNI:0000 0001 1507 4692)
2 Shinshu University School of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, Matsumoto, Japan (GRID:grid.263518.b) (ISNI:0000 0001 1507 4692); Yokohama City University Medical Center, Department of Inflammatory Bowel Disease, Yokohama, Japan (GRID:grid.413045.7) (ISNI:0000 0004 0467 212X)
3 Japanese Red Cross Society Suwa Red Cross Hospital, Department of Medical Oncology, Suwa, Japan (GRID:grid.416766.4) (ISNI:0000 0004 0471 5679)
4 Japanese Red Cross Society Suwa Red Cross Hospital, Department of Gastroenterology, Suwa, Japan (GRID:grid.416766.4) (ISNI:0000 0004 0471 5679)
5 Tokyo Yamate Medical Center, Center for Inflammatory Bowel Disease, Tokyo, Japan (GRID:grid.416089.2)
6 Shinshu University School of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, Matsumoto, Japan (GRID:grid.263518.b) (ISNI:0000 0001 1507 4692); Shinshu University, Department of Life Innovation, Institute for Biomedical Sciences, Matsumoto, Japan (GRID:grid.263518.b) (ISNI:0000 0001 1507 4692)